Abstract:Objective: The aim of this study was to evaluate the effect of low-dose alendronate (ALN) treatment on bone mineral density (BMD) and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Methods: This study was a large-sample, randomized, open-label, prospective, multicenter, clinical trial with a 12-month follow-up. A total of 639 postmenopausal women (aged 62.2 +/- 7.0 y) with osteopenia or osteoporosis were randomized into two groups: low-dose ALN (70 mg every two weeks) and standard-dose ALN (70 mg weekly). All patients were also supplemented with calcium (600 mg) and vitamin D-3 (125 IU) daily. BMD (measured by dual-energy x-ray absorptiometry; Hologic and Lunar) and levels of serum bone turnover markers (bone resorption marker, carboxy-telopeptide of type I collagen; bone formation marker, alkaline phosphatase) were assessed at baseline and at 3, 6, and 12 months of treatment. BMD and bone turnover markers were compared between the baseline and the end of treatment, and the changes in BMD and bone turnover markers were also compared between the low-dose ALN group and the standard-dose ALN group. Results: No significant differences in age, years since menopause, body mass index, BMD, 25-hydroxy vitamin D level, and serum biochemical markers were found at baseline between the two dose groups. A total of 558 (87.3%) and 540 (84.5%) women completed the treatment at the 6th and 12th months, respectively. After the 12-month treatment, lumbar spine and hip BMD increased and serum bone turnover markers decreased significantly in both of the treatment groups (P < 0.01), and no differences in percentage changes in BMD at the lumbar spine, femoral neck, and hip were found between the low-dose group (5.60%, 3.87%, and 3.28%, respectively) and the standard-dose group (5.07%, 2.93%, and 3.80%, respectively; P > 0.05). However, levels of serum alkaline phosphatase and carboxy-telopeptide of type I collagen in the standard-dose group decreased moderately compared with those in the low-dose group (P < 0.05 and P < 0.01). The women tolerated the two doses of ALN quite well. Adverse effects were similar in the two groups. Conclusions: Treatment with low-dose ALN (70 mg every two weeks) in women with postmenopausal osteopenia or osteoporosis effectively increases lumbar spine and hip BMD, similar to treatment with standard-dose ALN. Low-dose ALN may be a cost-effective and safe protocol for treating osteopenia or osteoporosis in Chinese women.

Early predictive value of bone turnover markers for the changes of bone mineral densities in postmenopausal patients with osteoporosis treated with alendronate

The effects of Alendronate on bone mineral density in RA patients with osteoporosis or osteopenia

The follow-up study of therapeutic effects of alendronate sodium on osteoporosis

The Efficacy of 3 Years Alendronate Therapy in Postmenopausal Chinese Women with Osteoporosis

Effect of Alendronate on Bone Mass in Women with Postmenopausal Osteoporosis or Osteopenia

The Efficacy of Alendronate in the Prevention and Treatment of Postmenopausal Osteoporosis

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis.

Effect of alendronate on bone turnover biomarkers in postmenopausal osteoporosis

[Effects of Alendronate on Bone Mineral Density, Cytokines and Indices of Bone Metabolism in Postmenopausal Osteoporotic Patients].

Comparison of the therapeutic effects of alendronate and zoledronic acid in postmenopausal women with osteoporosis

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.

The Efficacy and Tolerability of Once-Weekly Alendronate 70 Mg on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Chinese Women with Osteoporosis

Early Monitoring of Osteoporosis Treatment Response by Technetium-99M-methylene Diphosphonate Bone Scan.

Pre-treatment bone turnover does not influence the level of the response to alendronate in postmenopausal osteoporosis at the bone tissue level

The Therapeutic Response to Alendronate in Chinese Postmenopausal Women with Osteoporosis and the AluⅠ Polymorphism of Estrogen Receptor Β Gene

Study of Ibandronate and Alendronate Treatment for Postmenopausal Osteoporosis

Effectiveness of Alendronate in Treating Osteoporosis and Its Relationship with N740N Polymorphism of Low-density Lipoprotein Receptor Related Protein 5 Gene

Therapeutic Effect of Alendronate on Osteoporosis

Age-related Changes of Serum Bone Alkaline Phosphatase and Cross-Linked C-telopeptides of Type I Collagen and the Relationship with Bone Mineral Density in Chinese Women